ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
The presentation will outline the activity of ARIUS' anti-CD9 antibody, AR40A746.2.3, against acute myeloid leukemia (AML). The long-term survival expectation for patients with AML is poor due to disease relapse and resistance to chemotherapy. CD9 appears to be an important driver for leukemia and potentially other cancer stem cells, which often survive treatment, continue to multiply and go on to seed new tumors. Studies of patients with different types of cancer have demonstrated that the presence of CD9 can be linked to lower survival rates. AR40A746.2.3 has previously been found to control tumor growth and improve survival in pre-clinical breast and pancreatic cancer models.
"Since some cancer stem cells have been shown to be highly resistant to traditional cancer therapies and are believed to contribute to treatment resistance, the selectivity of ARIUS' anti-CD9 antibody for leukemic cancer stem cells represents an exciting opportunity in cancer therapy," said Dr. John E. Dick. "The ability to target leukemic cancer stem cells while potentially leaving normal stem cells intact may provide a more effective means for increasing survival and decreasing relapse in AML and possibly other forms of leukemia."
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.